Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Apr 17, 2026 · Filed Apr 21, 2026
Incyte's President, Global Head of R&D sold $1.8M of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,801,366
Shares × reported transaction price
66 days after results of Feb 10, 2026, 11 days before results of Apr 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $97.82 on Apr 17, 2026, 72% above its 52-week low and 12% below its high, little changed over the previous 30 trading days
52-week range $56.80 (Apr 21, 2025) to $110.57 (Jan 7, 2026), 76% of the way up, from 250 adjusted closes. 30 trading days earlier: $97.33 on Mar 5, 2026. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Jakafi XR on May 1, 2026, 14 days after this trade.
New drug application approved. Active ingredient: Ruxolitinib Phosphate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.4% | +0.1% | +2.4% |
| 30 days | +0.4% | +4.8% | -4.4% |
| 90 days | +21.4% | +5.2% | +16.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$1.42M of Incyte
Automatic saleDerivative exercise or conversion — not an open-market buy.